Presymptomatic compensation in Parkinson's disease is not dopamine-mediated - PubMed (original) (raw)
Review
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
Erwan Bezard et al. Trends Neurosci. 2003 Apr.
Abstract
The symptoms of Parkinson's disease (PD) appear only after substantial degeneration of the dopaminergic neuron system (e.g. an 80% depletion of striatal dopamine)--that is, there is a substantive presymptomatic period of the disease. It is widely believed that dopamine-related compensatory mechanisms are responsible for delaying the appearance of symptoms. Recent advances in understanding the presymptomatic phase of PD have increased our understanding of these dopamine-related compensatory mechanisms and have highlighted the role of non-dopamine-mediated mechanisms both within and outside the basal ganglia. This increased knowledge of plasticity within cortical-basal-ganglia-thalamocortical circuitry as dopaminergic neuron degeneration progresses has implications for understanding plasticity in neural circuits generally and, more specifically, for developing novel therapeutics or presymptomatic diagnostics for PD.
Comment in
- How does Parkinson's disease begin? The role of compensatory mechanisms.
Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez Diaz M. Obeso JA, et al. Trends Neurosci. 2004 Mar;27(3):125-7; author reply 127-8. doi: 10.1016/j.tins.2003.12.006. Trends Neurosci. 2004. PMID: 15036875 No abstract available.
Similar articles
- Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R, Greenamyre JT. Betarbet R, et al. Exp Neurol. 2004 Oct;189(2):393-403. doi: 10.1016/j.expneurol.2004.05.041. Exp Neurol. 2004. PMID: 15380489 - How does Parkinson's disease begin? The role of compensatory mechanisms.
Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez Diaz M. Obeso JA, et al. Trends Neurosci. 2004 Mar;27(3):125-7; author reply 127-8. doi: 10.1016/j.tins.2003.12.006. Trends Neurosci. 2004. PMID: 15036875 No abstract available. - Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered.
Braak H, Del Tredici K. Braak H, et al. Exp Neurol. 2008 Jul;212(1):226-9. doi: 10.1016/j.expneurol.2008.04.001. Epub 2008 Apr 15. Exp Neurol. 2008. PMID: 18501351 - Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification.
Blesa J, Trigo-Damas I, Dileone M, Del Rey NL, Hernandez LF, Obeso JA. Blesa J, et al. Exp Neurol. 2017 Dec;298(Pt B):148-161. doi: 10.1016/j.expneurol.2017.10.002. Epub 2017 Oct 4. Exp Neurol. 2017. PMID: 28987461 Review. - The globus pallidus, deep brain stimulation, and Parkinson's disease.
Dostrovsky JO, Hutchison WD, Lozano AM. Dostrovsky JO, et al. Neuroscientist. 2002 Jun;8(3):284-90. doi: 10.1177/1073858402008003014. Neuroscientist. 2002. PMID: 12061508 Review.
Cited by
- Alterations in the motor neuron-renshaw cell circuit in the Sod1(G93A) mouse model.
Wootz H, Fitzsimons-Kantamneni E, Larhammar M, Rotterman TM, Enjin A, Patra K, André E, Van Zundert B, Kullander K, Alvarez FJ. Wootz H, et al. J Comp Neurol. 2013 May 1;521(7):1449-69. doi: 10.1002/cne.23266. J Comp Neurol. 2013. PMID: 23172249 Free PMC article. - Correlates of movement initiation and velocity in Parkinson's disease: A longitudinal PET study.
Carbon M, Felice Ghilardi M, Dhawan V, Eidelberg D. Carbon M, et al. Neuroimage. 2007 Jan 1;34(1):361-70. doi: 10.1016/j.neuroimage.2006.08.019. Epub 2006 Oct 24. Neuroimage. 2007. PMID: 17064939 Free PMC article. - Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease.
Carrera I, Cacabelos R. Carrera I, et al. Curr Neuropharmacol. 2019;17(3):295-306. doi: 10.2174/1570159X17666181127125704. Curr Neuropharmacol. 2019. PMID: 30479218 Free PMC article. Review. - Enhancing and Extending Biological Performance and Resilience.
Leak RK, Calabrese EJ, Kozumbo WJ, Gidday JM, Johnson TE, Mitchell JR, Ozaki CK, Wetzker R, Bast A, Belz RG, Bøtker HE, Koch S, Mattson MP, Simon RP, Jirtle RL, Andersen ME. Leak RK, et al. Dose Response. 2018 Aug 15;16(3):1559325818784501. doi: 10.1177/1559325818784501. eCollection 2018 Jul-Sep. Dose Response. 2018. PMID: 30140178 Free PMC article. Review. - Clinical severity in Parkinson's disease is determined by decline in cortical compensation.
Johansson ME, Toni I, Kessels RPC, Bloem BR, Helmich RC. Johansson ME, et al. Brain. 2024 Mar 1;147(3):871-886. doi: 10.1093/brain/awad325. Brain. 2024. PMID: 37757883 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical